Inogatran

Drug Profile

Inogatran

Alternative Names: H 314/27; HA 31427

Latest Information Update: 09 Mar 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Amino acids; Antiplatelets; Piperidines; Small molecules
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Angina pectoris; Myocardial infarction; Unstable angina pectoris

Most Recent Events

  • 09 Mar 2000 A re-analysis of data from the TRIM trial has been added to the Ischaemic Heart Disease and Thromboses therapeutic trials section
  • 09 Jun 1999 A clinical study has been added to the Ischaemic Heart Disease and Thromboses pharmacodynamics section
  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top